ENJP
CONTACT

※The timeline may change depends on each project.

  • In need of codon optimization and UTR?

    Tailored mRNA design
    at your fingertips

  • In need of clinical or commercial mRNA/LNP?

    Brand new cGMP facility dedicated to manufacturing of mRNA/LNP

  • In need of rapid development?

    Achieve success in just 3 months - the fastest route to your development journey

  • In need of simplification?

    One stop solution to simplify outsourcing

  • In need of large production capacity?

    Up to 100g mRNA batch

Contact

Why ARCALIS?

Your product, our passion and expertise

Fully integrated
development services

Fully integrated development services

Fully integrated
development services

・Discovery plasmid DNA template synthesis・Discovery mRNA synthesis・Disvocery LNP formulation・Analytical service for mRNA/LNP・GLP-Tox service・GMP plasmid DNA template manufacturing・GMP LNP formulation・Fill and Finish

cGMP compliant
mRNA and LNP
manufacturing services

cGMP compliant mRNA and LNP
manufacturing services

cGMP compliant
mRNA and LNP
manufacturing services

Capability:mRNA: up to 100 g /batch
LNP bulk: up to 200L

Quality

Quality

Quality

・Three-way pharmaceutical compatibility ・QMS

ARCALIS’ Minamisoma Facility

ARCALIS has built a cGMP mRNA drug substance manufacturing facility in Minamisoma City in July 2023, and the world’s first approved product applying self-amplifying mRNA technology vaccine is planning to commercialize from 2024.The Minamisoma campus will also include a separate drug product manufacturing facility. Once completed in 2026, ARCALIS can offer one-stop manufacturing and release testing of mRNA vaccines and therhapeutics.

Contact

Please select the content of your inquiry.

PRIVACY POLICY